[ad_1]
Vaccination with the anti-COVID serum produced by Johnson & Johnson will begin in Romania in mid-April, the Ministry of Health announced.
The Ministry of Health specified that this vaccine is administered in a single dose, which is an advantage both logistically and in terms of vaccinating as many people as possible in a short time.
Therefore, a single dose may be sufficient to elicit an immune response.
Preliminary data from the Johnson & Johnson vaccine clinical trial showed it to be 67% effective in preventing symptomatic illness and significantly reducing COVID-19 cases among immunized people.
Therefore, out of 19,630 vaccinated people, 116 developed COVID-19 symptoms. Of the 19,691 unvaccinated people, 348 developed symptoms of COVID-19
Furthermore, 28 days after vaccination, the hospitalization rate among vaccinated people was 0%.
The Johnson & Johnson clinical trial was conducted in several countries, including South Africa and Brazil, where emerging strains were already circulating at the time.
The vaccine is developed by Janssen, the pharmaceutical division of Johnson & Johnson.
According to Agerpres, Andrei Baciu, vice president of the National Committee for Coordination of Activities on COVID Vaccination (CNCAV), said that the first doses of serum produced by Johnson & Johnson will likely arrive in Romania in April and around 100,000 will be delivered.
Publisher: ML
